Form 10-Q Nurix Therapeutics, Inc. For: Feb 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Nurix (NRIX) PT Raised to $23 at RBC Capital
April 11, 2024 6:28 AM EDTRBC Capital analyst Gregory Renza raised the price target on Nurix (NASDAQ: NRIX) to $23.00 (from $22.00) while maintaining a Outperform rating.
The analyst comments "The 1Q fiscal 24 EPS report recapped NRIX's recent partnership extensions that expand the company's TPD footprint in the I&I space... More
JPMorgan Takeaways on Nurix (NRIX) Q1 Earnings
April 10, 2024 12:32 PM EDTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $30.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Nurix reported a 1Q loss per share of $0.76, with takeaways from the print being incremental to those from the companys AACR presentation, updated collaboration with SNY, and our recent discussion with mgmt. On NX-5948 (BTK degrader for B-cell malignancies), the... More
